ResearcherHenan University of Chinese MedicineActive in the last 2 years
Xiangxiang Wu
Matched on ORCID iD 0000-0003-3623-1161; OpenAlex author ID A5018263505. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2022: 3 papers · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 7
- Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.ijpharm.2026.126996↗
- RGD peptide/dextran sulfate-based nanocarriers loaded with triptolide for double-targeted apoptosis of both tumor cells and M2-like TAMs in pancreatic cancer t… Co-author DOI 10.1016/j.ijbiomac.2025.144032↗
- Self-assembled triptolide prodrug nanovesicles loading with ginsenoside Rg3 for double-targeted therapy of pancreatic cancer. Co-author DOI 10.1016/j.mtbio.2025.102004↗
- Synergistic effect of pH-sensitive PEGylated RG3-chitosan prodrug nanoparticles encapsulated celastrol on pancreatic cancer. Co-author DOI 10.1080/10717544.2025.2464189↗
- Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. Co-author DOI 10.1080/10717544.2021.2018521↗
- A mitochondria-targeted nano-platform for pancreatic cancer therapy. Last author DOI 10.3389/fchem.2022.951434↗
- TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. Last author DOI 10.3390/molecules27123686↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Huahui Zeng · 3 shared papers, 2025 · strength 0.79
- Paper Self-assembled triptolide prodrug nanovesicles loading with ginsenoside Rg3 for double-targeted therapy of pancreatic c… DOI 10.1016/j.mtbio.2025.102004↗
- Paper Synergistic effect of pH-sensitive PEGylated RG3-chitosan prodrug nanoparticles encapsulated celastrol on pancreatic ca… DOI 10.1080/10717544.2025.2464189↗
- Paper RGD peptide/dextran sulfate-based nanocarriers loaded with triptolide for double-targeted apoptosis of both tumor cells… DOI 10.1016/j.ijbiomac.2025.144032↗
- Huahui Zeng · 4 shared papers, 2022–2026 · strength 0.75
- Paper Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. DOI 10.1016/j.ijpharm.2026.126996↗
- Paper TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. DOI 10.3390/molecules27123686↗
- Paper Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer. DOI 10.1080/10717544.2021.2018521↗
- Jiaxing Wang · 2 shared papers, 2025–2026 · strength 0.58
- Paper Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. DOI 10.1016/j.ijpharm.2026.126996↗
- Paper Self-assembled triptolide prodrug nanovesicles loading with ginsenoside Rg3 for double-targeted therapy of pancreatic c… DOI 10.1016/j.mtbio.2025.102004↗
- Zhengxian Zhang · 2 shared papers, 2025–2026 · strength 0.57
- Paper Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. DOI 10.1016/j.ijpharm.2026.126996↗
- Paper RGD peptide/dextran sulfate-based nanocarriers loaded with triptolide for double-targeted apoptosis of both tumor cells… DOI 10.1016/j.ijbiomac.2025.144032↗
- Zhenqiang Zhang · 2 shared papers, 2022–2025 · strength 0.40
- Xiaoke Tan · 2 shared papers, 2022 · strength 0.29
- Zheng Zhang · 1 shared paper, 2025 · strength 0.27
- Yaning Ge · 1 shared paper, 2025 · strength 0.26
- Xinlong Wang · 1 shared paper, 2022 · strength 0.15
- Xiaohu Zeng · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.